Black Diamond Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $3.45
- Today's High:
- $3.6
- Open Price:
- $3.47
- 52W Low:
- $1.18
- 52W High:
- $4.08
- Prev. Close:
- $3.48
- Volume:
- 249542
Company Statistics
- Market Cap.:
- $90.19 million
- Book Value:
- 2.689
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -31.23%
- Return on Equity TTM:
- -63.92%
Company Profile
Black Diamond Therapeutics Inc had its IPO on 2020-01-30 under the ticker symbol BDTX.
The company operates in the Healthcare sector and Biotechnology industry. Black Diamond Therapeutics Inc has a staff strength of 65 employees.
Stock update
Shares of Black Diamond Therapeutics Inc opened at $3.47 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $3.45 - $3.6, and closed at $3.55.
This is a +2.01% increase from the previous day's closing price.
A total volume of 249,542 shares were traded at the close of the day’s session.
In the last one week, shares of Black Diamond Therapeutics Inc have slipped by -0.28%.
Black Diamond Therapeutics Inc's Key Ratios
Black Diamond Therapeutics Inc has a market cap of $90.19 million, indicating a price to book ratio of 0.404 and a price to sales ratio of 0.
In the last 12-months Black Diamond Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-88205000. The EBITDA ratio measures Black Diamond Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Black Diamond Therapeutics Inc’s operating margin was 0% while its return on assets stood at -31.23% with a return of equity of -63.92%.
In Q1, Black Diamond Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Black Diamond Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-3.01 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Black Diamond Therapeutics Inc’s profitability.
Black Diamond Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.6459. Its price to sales ratio in the trailing 12-months stood at 0.
Black Diamond Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $135.58 million
- Total Liabilities
- $12.85 million
- Operating Cash Flow
- $24.81 million
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Black Diamond Therapeutics Inc ended 2024 with $135.58 million in total assets and $0 in total liabilities. Its intangible assets were valued at $135.58 million while shareholder equity stood at $-355864000.00.
Black Diamond Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $12.85 million in other current liabilities, 5000.00 in common stock, $-355864000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $39.14 million and cash and short-term investments were $103.37 million. The company’s total short-term debt was $2,908,000 while long-term debt stood at $0.
Black Diamond Therapeutics Inc’s total current assets stands at $107.98 million while long-term investments were $0 and short-term investments were $64.23 million. Its net receivables were $0 compared to accounts payable of $3.05 million and inventory worth $0.
In 2024, Black Diamond Therapeutics Inc's operating cash flow was $24.81 million while its capital expenditure stood at $0.
Comparatively, Black Diamond Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $3.55
- 52-Week High
- $4.08
- 52-Week Low
- $1.18
- Analyst Target Price
- $6.5
Black Diamond Therapeutics Inc stock is currently trading at $3.55 per share. It touched a 52-week high of $4.08 and a 52-week low of $4.08. Analysts tracking the stock have a 12-month average target price of $6.5.
Its 50-day moving average was $3.79 and 200-day moving average was $2.51 The short ratio stood at 35.5 indicating a short percent outstanding of 0%.
Around 402.8% of the company’s stock are held by insiders while 7550.2% are held by institutions.
Frequently Asked Questions About Black Diamond Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Black Diamond Therapeutics, Inc., a clinical-stage precision oncology medicine company, focuses on the discovery and development of therapies for patients with genetically defined cancers. The company’s lead product candidate, BDTX-1535, a brain-penetrant, mutant selective, irreversible EGFR MasterKey inhibitor, designed to inhibit a family of oncogenic mutations, currently under Phase 1 clinical trial. It also develops BDTX-4933, a brain penetrant RAF MasterKey inhibitor, designed to be a brain penetrant and highly selective and potent inhibitor of oncogenic BRAF Class I, II, III and active RAF dimers, expected to initiate Phase 1 clinical trial. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.